Vessby B, Lithell H, Boberg J, Hellsing K, Werner I
Proc R Soc Med. 1976;69 Suppl 2(Suppl 2):32-7. doi: 10.1177/00359157760690S208.
The efficacy of gemfibrozil in lowering increased serum lipoprotein concentrations was tested in a placebo-controlled cross-over trial on 30 patients. Administered in a dose of 1200 mg daily, gemfibrozil reduced increased serum triglyceride levels by approximately 50% and reduced increased serum cholesterol concentrations by about 20%. Elevated VLDL triglyceride levels were reduced by 60%, and increased LDL cholesterol concentrations were reduced by approximately 20%. The mean HDL cholesterol concentration increased during gemfibrozil treatment. No adverse reactions attributable to gemfibrozil were recorded during the trial.
在一项针对30名患者的安慰剂对照交叉试验中，测试了吉非贝齐降低升高的血清脂蛋白浓度的疗效。以每日1200毫克的剂量给药时，吉非贝齐可使升高的血清甘油三酯水平降低约50%，并使升高的血清胆固醇浓度降低约20%。升高的极低密度脂蛋白甘油三酯水平降低了60%，升高的低密度脂蛋白胆固醇浓度降低了约20%。在吉非贝齐治疗期间，高密度脂蛋白胆固醇的平均浓度有所增加。试验期间未记录到任何可归因于吉非贝齐的不良反应。
